Antonio J. León-González

Dr. Antonio J. León-González

1. Department of Pharmacology, Faculty of Pharmacy, University of Seville. Profesor García González Street 2, 41012 Seville, Spain
+1
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2015 in Biochemical Pharmacology
Verified
Journal Article
Closed access
Antonio J. León-GonzálezAntonio J. León-González
Antonio J. León-González
CACyril Auger
Cyril Auger
VSValérie Schini-Kerth
Valérie Schini-Kerth

1 June 2012 in Current Drug Targets
Verified
Journal Article
Closed access
PDF file
CCCarmen Martin Cordero
Carmen Martin Cordero
Antonio J. León-GonzálezAntonio J. León-González
Antonio J. León-González
JMJOSÉ MANUEL CALDERÓN MONTAÑO
JOSÉ MANUEL CALDERÓN MONTAÑO
EBEstefanía Burgos
Estefanía Burgos
MLMiguel Lopez-Lazaro
Miguel Lopez-Lazaro
Cancer cells produce high levels of reactive oxygen species (ROS) that lead to a state of increased basal oxidative stress. Since this state of oxidative stress makes cancer cells vulnerable to agents that further augment ROS levels, the use of pro-oxidant agents is emerging as an exciting strategy to selectively target tumor cells. Natural products have provided a significant contribution to the development of several drugs currently used in cancer chemotherapy. Although many natural products are known to affect the redox state of the cell, most studies on these compounds have focused on their antioxidant activity instead of on their pro-oxidant properties. This article provides an overview of natural products with pro-oxidant and anticancer activities, with special focus on plant secondary metabolites, and discusses their possible use as cancer chemotherapeutic agents.

17 January 2017 in Circulation
Verified
Journal Article
Closed access
PDF file
MAMalak Abbas
Malak Abbas
LJLaurence Jesel
Laurence Jesel
CACyril Auger
Cyril Auger
LALamia Amoura
Lamia Amoura
NMNathan Messas
Nathan Messas
OMOlivier Morel
Olivier Morel
Background: Microparticles (MPs) have emerged as a surrogate marker of endothelial dysfunction and cardiovascular risk. This study examined the potential of MPs from senescent endothelial cells (ECs) or from patients with acute coronary syndrome (ACS) to promote premature EC aging and thrombogenicity.Methods: Primary porcine coronary ECs were isolated from the left circumflex coronary artery. MPs were prepared from ECs and venous blood from patients with ACS (n=30) and from healthy volunteers (n=4) by sequential centrifugation. The level of endothelial senescence was assessed as senescence-associated β-galactosidase activity using flow cytometry, oxidative stress using the redox-sensitive probe dihydroethidium, tissue factor activity using an enzymatic Tenase assay, the level of target protein expression by Western blot analysis, platelet aggregation using an aggregometer, and shear stress using a cone-and-plate viscometer.Results: Senescence, as assessed by senescence-associated β-galactosidase activity, was induced by the passaging of porcine coronary artery ECs from passage P1 to P4, and was associated with a progressive shedding of procoagulant MPs. Exposure of P1 ECs to MPs shed from senescent P3 cells or circulating MPs from ACS patients induced increased senescence-associated β-galactosidase activity, oxidative stress, early phosphorylation of mitogen-activated protein kinases and Akt, and upregulation of p53, p21, and p16. Ex vivo, the prosenescent effect of circulating MPs from ACS patients was evidenced only under conditions of low shear stress. Depletion of endothelial-derived MPs from ACS patients reduced the induction of senescence. Prosenescent MPs promoted EC thrombogenicity through tissue factor upregulation, shedding of procoagulant MPs, endothelial nitric oxide synthase downregulation, and reduced nitric oxide–mediated inhibition of platelet aggregation. These MPs exhibited angiotensin-converting enzyme activity and upregulated AT1 receptors and angiotensin-converting enzyme in P1 ECs. Losartan, an AT1 receptor antagonist, and inhibitors of either mitogen-activated protein kinases or phosphoinositide 3-kinase prevented the MP-induced endothelial senescence.Conclusions: These findings indicate that endothelial-derived MPs from ACS patients induce premature endothelial senescence under atheroprone low shear stress and thrombogenicity through angiotensin II–induced redox-sensitive activation of mitogen-activated protein kinases and phosphoinositide 3-kinase/Akt. They further suggest that targeting endothelial-derived MP shedding and their bioactivity may be a promising therapeutic strategy to limit the development of an endothelial dysfunction post-ACS.

19 October 2015 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
Antonio J. León-GonzálezAntonio J. León-González
Antonio J. León-González
N. AceroN. Acero
N. Acero
DMDolores Munoz-Mingarro
Dolores Munoz-Mingarro
INInmaculada Navarro
Inmaculada Navarro
CCCarmen Martin Cordero
Carmen Martin Cordero
Chalcones constitute a group of phenolic compounds that command an increasing interest on cancer research. Natural chalcones are widespread through the plant kingdom. The most abundant and investigated chalcones are isoliquiritigenin, flavokawain and xanthohumol, which are present in the Fabaceae, Piperaceae, Cannabaceae, and Moraceae families. These chalcones have been shown to be promising lead antitumor-chemopreventive drugs by three different activities: antioxidants, cytotoxic and apoptosis inducers. In the recent years, SAR (structure-activity relationship) has contributed towards the improvement of anticancer properties of chalcones by substituting aryl rings and introducing heterocyclic moieties. This review summarizes the anticancer activities shown by natural chalcones and the SAR and describes how different chemical moiety modifications could lead them to be therapeutically useful in the treatment of cancer.

13 May 2020 in Phytochemistry Reviews
Verified
Journal Article
Closed access
PDF file
MSMarina Sánchez-Hidalgo
Marina Sánchez-Hidalgo
Antonio J. León-GonzálezAntonio J. León-González
Antonio J. León-González
MGMarina Gálvez-Peralta
Marina Gálvez-Peralta
NGNuria H. González-Mauraza
Nuria H. González-Mauraza
CCCarmen Martin Cordero
Carmen Martin Cordero

11 March 2015 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MAMahmoud Alhosin
Mahmoud Alhosin
Antonio J. León-GonzálezAntonio J. León-González
Antonio J. León-González
IDIsraa Dandache
Israa Dandache
ALAgnès Lelay
Agnès Lelay
SRSherzad K. Rashid
Sherzad K. Rashid
VSValérie Schini-Kerth
Valérie Schini-Kerth
Defect in apoptosis has been implicated as a major cause of resistance to chemotherapy observed in B cell chronic lymphocytic leukaemia (B CLL). This study evaluated the pro-apoptotic effect of an anthocyanin-rich dietary bilberry extract (Antho 50) on B CLL cells from 30 patients and on peripheral blood mononuclear cells (PBMCs) from healthy subjects and determined the underlying mechanism. Antho 50 induced concentration- and time-dependent pro-apoptotic effects in B CLL cells but little or no effect in PBMCs. Among the main phenolic compounds of the bilberry extract, delphinidin-3-O-glucoside and delphinidin-3-O-rutinoside induced a pro-apoptotic effect. Antho 50-induced apoptosis is associated with activation of caspase 3, down-regulation of UHRF1, a rapid dephosphorylation of Akt and Bad and down-regulation of Bcl-2. Antho 50 significantly induced PEG-catalase-sensitive formation of reactive oxygen species in B CLL cells. PEG-catalase prevented the Antho 50-induced induction of apoptosis and related signaling. The present findings indicate that Antho 50 exhibits strong pro-apoptotic activity through redox-sensitive caspase 3 activation-related mechanism in B CLL cells involving dysregulation of the Bad/Bcl-2 pathway. This activity of Antho 50 involves the glucoside and rutinoside derivatives of delphinidin. They further suggest that Antho 50 has chemotherapeutic potential by targeting selectively B CLL cells.